Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Johnson and Johnson
AstraZeneca
Merck
McKesson

Last Updated: January 30, 2023

Cangrelor - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for cangrelor and what is the scope of freedom to operate?

Cangrelor is the generic ingredient in one branded drug marketed by Chiesi and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cangrelor has one hundred and sixteen patent family members in forty-three countries.

There are three drug master file entries for cangrelor. One supplier is listed for this compound.

Recent Clinical Trials for cangrelor

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mercy Health OhioPhase 3
Fondation Ophtalmologique Adolphe de RothschildPhase 3
University Hospital, CaenPhase 4

See all cangrelor clinical trials

Pharmacology for cangrelor
Paragraph IV (Patent) Challenges for CANGRELOR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KENGREAL For Injection cangrelor 50 mg/vial 204958 2 2019-06-24

US Patents and Regulatory Information for cangrelor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for cangrelor

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chiesi Farmaceutici S.p.A. Kengrexal cangrelor EMEA/H/C/003773
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
Authorised no no no 2015-03-23
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for cangrelor

Country Patent Number Title Estimated Expiration
Spain 2773040 See Plans and Pricing
Argentina 013157 COMPOSICION FARMACEUTICA QUE INCLUYE UN ANALOGO NUCLEOTIDO Y PROCESO PARA SU PREPARACION See Plans and Pricing
Canada 2724470 MAINTIEN DE L'INHIBITION PLAQUETTAIRE PENDANT UN TRAITEMENT ANTIPLAQUETTAIRE (MAINTENANCE OF PLATELET INHIBITION DURING ANTIPLATELET THERAPY) See Plans and Pricing
Denmark 2498731 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for cangrelor

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1007094 15C0060 France See Plans and Pricing PRODUCT NAME: CANGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,NOTAMMENT UN SEL TETRASODIQUE; REGISTRATION NO/DATE: EU/1/15/994/001 20150323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Express Scripts
Colorcon
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.